Molecular Partners AG (MOLN)
4.56
0.26 (6.05%)
At close: Mar 28, 2025, 3:29 PM
4.46
-2.27%
After-hours: Mar 28, 2025, 04:46 PM EDT
6.05% (1D)
| Bid | 3.84 |
| Market Cap | 168.28M |
| Revenue (ttm) | 5.39M |
| Net Income (ttm) | -58.56M |
| EPS (ttm) | -1.8 |
| PE Ratio (ttm) | -2.54 |
| Forward PE | -3.24 |
| Analyst | n/a |
| Ask | 5.31 |
| Volume | 3,919 |
| Avg. Volume (20D) | 3,936.4 |
| Open | 4.20 |
| Previous Close | 4.30 |
| Day's Range | 4.20 - 4.56 |
| 52-Week Range | 3.32 - 12.70 |
| Beta | 0.63 |
About MOLN
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for th...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2021
Employees 158
Stock Exchange NASDAQ
Ticker Symbol MOLN
4 months ago
+14.18%
Molecular Partners shares are trading higher after...
Unlock content with
Pro Subscription
9 months ago
+13.78%
Molecular Partners shares are trading higher after the comapny announced preclinical proof-of-concept data from MP0621.
2 months ago · seekingalpha.com
Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical ProgramsMolecular Partners AG leverages a novel DARPin platform for targeted cancer therapies, with promising early-stage candidates like MP0533 and MP0317 in clinical trials. Financially, MOLN has a cash run...